EGFR and head and neck squamous cell carcinoma: In the context of HNSCC, we previously reviewed how the combined use cetuximab, as an anti-EGFR ADCC-inducing antibody, with NK cell targeting immunotherapies could control tumor outgrowth and restore immune-mediated antitumor function (55).